Hospira, Inc.
<b>Headquarters</b>
275 North Field Drive
Lake Forest
Illinois
60045
United States
Tel: 224-212-2000
Website: http://www.hospira.com/
About Hospira, Inc.
Hospira is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™ by developing, manufacturing and marketing products that improve the productivity, safety and efficacy of patient care. Created from the core global hospital products business of Abbott Laboratories in April 2004, Hospira has a 70-year history of service to the hospital industry.In February 2007, Hospira acquired MaynePharma Limited to become the world leader in specialty generic injectable pharmaceuticals. Through its offering of high-quality, lower-cost alternatives to proprietary medications, Hospira continues to help reduce the overall costs of healthcare – to improve both the affordability of care for patients and the financial strength of the global healthcare system. The company also is a pioneer in providing innovative solutions to improve patient and healthcare worker safety. Its portfolio includes one of the industry's broadest lines of generic acutecare and oncology injectables, and integrated solutions for medication management and infusion therapy.
OPERATIONS Nine manufacturing facilities in the United States include: Ashland, Ohio; Austin, Texas; Boulder, Colo.; Buffalo, N.Y.; Clayton, N.C.; McPherson, Kan.; Morgan Hill, Calif.; Rocky Mount, N.C. Nine facilities outside the United States include: Aguadilla, Puerto Rico; Haina, Dominican Republic; La Aurora de Heredia, Costa Rica; Liscate, Italy; Montreal, Canada; Mulgrave, Australia; Salisbury, Australia; Sligo, Ireland; and Wasserburg, Germany.
COMPANY LEADERSHIP • John C. Staley, Chairman of the Board of Directors • Mike Ball, Chief Executive Officer (CEO)
CUSTOMERS Hospira has established long-standing customer relationships that span the "continuum of care" (hospitals, alternate site facilities, home healthcare providers and long-term care facilities).
MAJOR BUSINESSES/PRODUCTS Hospira has a leading position in the manufacture and supply of a broad range of hospital products including:
• Specialtyinjectables (including generic acute-care and oncology injectables, intensive-care proprietary pharmaceuticals, as well as proprietary delivery systems such as the iSecure™ syringe, a pre-filled, ready-to-use, disposable syringe) • Medication management systems (including electronic infusion pumps and the HospiraMedNet® software system) • Infusion therapy solutions/supplies (including the VisIV™ next-generation container) • Critical care devices • Third-party contract manufacturing, which leverages Hospira's expertise in pharmaceutical manufacturing
Hospira's news releases and other information can be found at www.hospira.com.
367 articles about Hospira, Inc.
-
Between top-notch academic institutions, solid venture capital funding, expanding lab space and governmental support, Chicago is emerging as a true hotbed for biotech growth.
-
Part of the Trump Administration and the U.S. Food and Drug Administration (FDA)’s strategy to push down drug prices is to develop ways to increase competition. As such, the agency launched a Drug Competition Action Plan that has several components.
-
In August, Pfizer filed with the U.S. Food and Drug Administration (FDA) accusing Amgen and Roche of using social media to mislead doctors and patients about biosimilars and their effectiveness.
-
The U.S. Food and Drug Administration (FDA) recently reprimanded AbbVie for its processes for investigating reports of deaths associated with three of its drugs.
-
The U.S. Food and Drug Administration (FDA) approved Pfizer’s Retacrit (epoetin alfa-epbx), a biosimilar to Amgen’s Epogen/Procrit (epoetin alfa). The drugs treat anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in HIV patients.
-
FDA approves first epoetin alfa biosimilar for the treatment of anemia
5/15/2018
The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) for the treatment of anemia
-
The U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) to Sandoz, a division of Novartis, for its Biologics Licensing Application (BLA) for its biosimilar to Roche/Genentech’s Rituxan.
-
Here’s a look at the top six generic drug companies to work for.
-
Advanced Pharmaceuticals, D/B/A Avella Of Houston Issues Voluntary Nationwide Recall Of Specific Lots Of Potassium Phosphate And Succinylcholine Repacked And/Or Compounded At Its Houston Location As A Result Of Hospira's June 15, 2017 Recall Of Such Produ
6/23/2017
-
ICU Medical Completes The Acquisition Of Hospira Infusion Systems From Pfizer
2/6/2017
-
Omnicell's Performance Center Integrates With Hospira's Infusion Pump Software
12/1/2016
-
After Cutting Hundreds of Hospira-Related Jobs, Pfizer Sells Hospira Infusion Systems Biz in in $1 Billion Deal
10/6/2016
-
Pfizer to Shut Down Four Hospira Distribution Centers
8/24/2016
-
Hospira Launches Lifecare PCA 7.0 Infusion System, First PCA Pump That Integrates With The Electronic Medical Record
5/19/2016
-
Pfizer Rumored to be Selling Its Hospira Pumps Division, With Smiths Group, Fresenius SE and Pamplona Capital Bidding
5/3/2016
-
Novartis AG Taps Former Hospira CEO to Rescue Alcon
1/28/2016
-
Pfizer Mulls Over Selling Hospira's Pump Unit for ~$2 Billion
1/14/2016
-
Pfizer Commences Exchange Offers For Hospira Notes
9/4/2015
-
As Pfizer Closes Hospira Acquisition, Analysts Speculate About Spinoff
9/4/2015
-
Pfizer Completes Acquisition Of Hospira
9/3/2015